Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.50 |
| ▸ | AR | P10275 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630701 | 0.91 | PGR (0.60) | PGRNR3C1NR3C2ARMEN1 | |
| SCHEMBL1629735 | 0.80 | PGR (0.41) | PGRNR3C1NR3C2ARMEN1 | |
| SCHEMBL1629432 | 0.80 | ASH1L (0.47) | PGRNR3C1NR3C2ARMEN1 | |
| SCHEMBL1629260 | 0.78 | NR3C1 (0.52) | PGRNR3C1NR3C2ARMEN1 | |
| SCHEMBL4106338 | 0.77 | KDM1A (0.40) | PGRNR3C1NR3C2ARASH1L | |
| SCHEMBL14471984 | 0.76 | PGR (0.84) | PGRNR3C1NR3C2AR | |
| SCHEMBL14471985 | 0.76 | PGR (0.84) | PGRNR3C1NR3C2AR | |
| SCHEMBL1630954 | 0.76 | PGR (0.43) | PGRNR3C1NR3C2ARMEN1 | |
| SCHEMBL14472021 | 0.76 | PGR (0.84) | PGRNR3C1NR3C2AR | |
| SCHEMBL1630690 | 0.75 | NR3C1 (0.43) | PGRNR3C1NR3C2ARMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979314-B1 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7932284-B2 | Indole sulfonamide modulators of progesterone receptors | ELI LILLY AND COMPANY (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | PGR, NPSR1, PRLHR | PGR 1/4885NR3C1 63/4885NR3C2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.